The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering ...

Critics say the meta-analysis provides an inaccurate picture of anti-amyloid medications. Two of them have FDA approval.

A new medical review finds "trivial" benefits for amyloid drugs. See why U.S. experts say these findings may not tell the ...

For the millions of families watching a loved one slip away to Alzheimer’s disease, the arrival of drugs that promised to ...

Top drugmakers have spent more than a decade investigating and advancing anti-amyloid Alzheimer's medicines in clinical ...

Please provide your email address to receive an email when new articles are posted on . Cell transformation begins with slow degeneration and progresses rapidly. The data confirmed results from ...

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

From studying the human genome, to analyzing the way proteins are encoded, or monitoring RNA expression, researchers are rapidly gaining a far richer understanding of the complex genetic and cellular ...

The FDA recently cleared the Lumipulse blood test for early diagnosis of Alzheimer's disease in people 55 and over with memory loss. The noninvasive Lumipulse blood test measures the levels of two ...

Alzheimer's disease affects more than 55 million people worldwide, and that number is projected to nearly triple by 2050. It ...

Is Alzheimer's a gut disease? AI research links appendix removal and specific dietary patterns to a significantly higher risk ...